Skip to main content

Table 2 SLEDAI-qualifying manifestations are associated with decreased ability to degrade chromatin from multiple sources

From: A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources

Manifestation Total NET Primary necrotic chromatin Secondary necrotic chromatin
n = 20/46 n = 41/25 n = 9/56
(% low/% normal) (% low/% normal) (% low/% normal)
Seizure 0 0/0 0/0 0/0
Psychosis 0 0/0 0/0 0/0
Organic brain syndrome 0 0/0 0/0 0/0
Visual disturbance 1 0/2.2 2.4/0 0/1.8
Lupus headache 0 0/0 0/0 0/0
Cerebrovascular accident 0 0/0 0/0 0/0
Vasculitis 5 15/4.4 4.9/12 11/7.2
Arthritis 8 10/13 12/12 11/13
Myositis 1 5/0 2.4/0 11/0*
Glomerulonephritis     
Cylenduria 5 15/4.4 9.8/4 11/7
Hematuria 10 20/13 17/12 33/13
Proteinuria 13 30/15 22/16 44/16*
Pyuria 5 20/2.2* 9.8/4 22/5.4
Rash 10 15/15 15/16 11/16
Alopecia 9 20/11 20/4 22/13
Mucosal ulcers 8 15/11 17/4 22/11
Pleuritis 3 5/4.4 4.9/4 11/3.6
Pericarditis 0 0/0 0/0 0/0
Low complement 23 35/35 39/28 56/30
dsDNA antibodies 22 75/15*** 41/20 67/27*
Fever 4 5/6.5 9.8/0* 0/7.1
Thrombocytopenia 0 0/0 0/0 0/0
Leukopenia 4 5/6.5 4.9/8 0/7.1
  1. Clinical manifestations during the time of sample collection were divided into groups according to their ability to degrade neutrophil extracellular traps (NETs), primary and secondary necrotic chromatin. Total patients with manifestation are indicated in the first column. For each source of DNA the total number of patients with low-versus-normal degrading ability are indicated and percent of patients with low-versus-normal degrading ability are indicated for each respective manifestation. Significance of differences were calculated using Pearson’s χ2 test: *p <0.05: and ***p <0.001; increased proportions in bold text